Viewing data from:

TESTOSTERONE ENANTHATE

ANDA

TESTOSTERONE ENANTHATE | A040575 | NEXUS PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Testosterone Enanthate (2023)

Total Spending

$851K

Total Claims

10,411

Beneficiaries

3,568

Avg Cost/Unit

$13.74

Spending Trend

$706K(2019)→$748K(2020)→$754K(2021)→$722K(2022)→$851K(2023)

YoY Change:+3.9%

5yr CAGR:+1.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs3 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

BAYER AGTESTOSTERONE ENANTHATE

DMF 33911978

ASPEN OSS BVTESTOSTERONE ENANTHATE

DMF 38771980

STEROID SPATESTOSTERONE ENANTHATE

DMF 327652018

ROUSSELL UCLAFInactiveTESTOSTERONE ENANTHATE

DMF 37811980

PHARMACIA AND UPJOHNInactiveTESTOSTERONE ENANTHATE USP

DMF 42391981

BIOVET JOINT STOCK COInactiveTESTOSTERONE ENANTHATE

DMF 239202010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 200MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jun 14, 2006

No patent or exclusivity listings for this strength.